In a research note titled "Pima' P3 & P2 Trial Risk May Be a Visual Hallucination," Cantor Fitzgerald analyst Charles Duncan reiterates an Overweight rating on Acadia Pharmaceuticals with a $25 price target. For Nuplazid, the analyst says that while he's cautious on near-term revenue growth, he believes new patient additions should resume as an awareness campaign gains traction in 2018. Further, based on his recent due diligence, Duncan sees a broadening clinical evaluation of pimavanserin as fueling long-term growth. He believes the probability of success for current studies is underappreciated at current trading levels.